Clinical Trials Directory

Trials / Completed

CompletedNCT02133768

Routine Bladder Catheterisation Through Fast-track Hip and Knee Replacement - What Are the Consequences?

Status
Completed
Phase
Study type
Observational
Enrollment
800 (actual)
Sponsor
Lundbeck Foundation · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

To describe the need for re-catheterization and incidence of urological complications of routine use of perioperative fixed urinary catheter (KAD) for up to 24 hours of fast-track THA and TKA

Detailed description

Postoperative urinary retention (POUR) is a well known complication of fast-track total hip (THA) and knee arthroplasty (TKA), and even though medical options have been attempted, bladder catheterisation remains the only well-documented capacity to prevent and / or treat POUR. It was previously standard to use fixed urinary catheter (KAD), the first 24-48 hours postoperatively to prevent POUR by THA and TKA, while more recent studies now recommend intermittent urinary catheterization in the postoperative period. However, there are no detailed studies with adequate follow-up, describing the consequences of using either one or the other treatment regimen of POUR by fast-track THA and TKA. Purpose: To describe the need for re-catheterization and incidence of urological complications of routine use of perioperative fixed urinary catheter (KAD,catheter a demure) for up to 24 hours of fast-track THA and TKA End Points: 1. The number of patients in need of re-catheterization due POUR 2. The number of patients in which the removal of KAD was not carried out within 24 hours. 3. The number of urinary tract infections from surgery to postoperative day (POD) 30 4. The number of patients with new-onset urinary discomfort at POD 30 (Increase in IPSS score). 5. The number of urological-related readmissions (including urosepsis) within POD 30

Conditions

Timeline

Start date
2014-05-01
Primary completion
2016-05-01
Completion
2016-06-01
First posted
2014-05-08
Last updated
2017-03-07

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT02133768. Inclusion in this directory is not an endorsement.